Search

Your search keyword '"Isabelle Monnet"' showing total 464 results

Search Constraints

Start Over You searched for: Author "Isabelle Monnet" Remove constraint Author: "Isabelle Monnet"
Sorry, I don't understand your search. ×
464 results on '"Isabelle Monnet"'

Search Results

1. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry

2. Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study)

3. Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14)

4. Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts’ studies

5. Unravelling the secrets of the resistance of GaN to strongly ionising radiation

6. Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival

7. Paclitaxel–bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study

8. Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)

9. Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial 'at progression' cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis

10. Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

11. PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 'EPNEC' study

12. Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC

13. Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis

14. Risk factors for early mortality from lung cancer: evolution over the last 20 years in the French nationwide KBP cohorts

15. Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)

16. Risk factors for early mortality from lung cancer: evolution over the last 20 years in the French nationwide KBP cohorts

17. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

18. Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)

19. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry

20. A defect of amphiregulin release predicted longer survival independently of <scp>YAP</scp> expression in patients with pleural mesothelioma in the <scp>IFCT</scp> ‐0701 <scp>MAPS</scp> phase 3 trial

21. Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018

22. Supplementary Data 1 from Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial

23. Data from Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non–Small Cell Lung Cancer

24. Data from Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial

25. Clinicopathologic Features and Response to Therapy ofNRG1Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry

26. Monitoring of the recovery of ion-damaged 4H-SiC with in-situ synchrotron X-ray diffraction as a tool for strain-engineering

27. Damage in InGaN/GaN bilayers upon Xe and Pb swift heavy ion irradiation

28. Iron and steel corrosion mechanisms in a carbonate rich pore water: Multiscale characterization of the corrosion product layers

29. Localised corrosion of iron and steel in the Callovo-Oxfordian porewater after 3 months at 120 °C: Characterizations at micro and nanoscale and formation mechanisms

30. Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients withBRAF-Mutant Metastatic Non–Small Cell Lung Cancer

32. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial

33. Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival

34. Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST study

35. Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study

36. Structural and mechanical modifications of GaN thin films by swift heavy ion irradiation

37. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer

38. Cover Picture: Materials and Corrosion. 1/2023

40. Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02–15 study)

41. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort

42. EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy

43. Five year survival update from KEYNOTE-010

44. Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations

45. Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine–atezolizumab combination for stage-IV non-small-cell lung cancer – VinMetAtezo trial, (GFPC‡ 04-2017)

46. Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

47. Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)

48. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort

49. Etiological Work-Up for Adults with Bronchiectasis: A Predictive Diagnostic Score for Primary Ciliary Dyskinesia and Cystic Fibrosis

50. Near-surface modification of defective KTaO3 by ionizing ion irradiation

Catalog

Books, media, physical & digital resources